Drugs, such as celecoxib and rofecoxib, which selectively inhibit the COX-2 enzyme, are as efficacious as other non-steroidal antiinflammatory drugs, but reduce the risk of serious gastrointestinal bleeding and ulceration. However, the improved tolerance of the COX-2 selective inhibitors may come at the cost of an increased risk of thrombosis in patients with ischaemic heart disease if they are not also taking aspirin. Like the older non-steroidal anti-inflammatory drugs, the COX-2 selective inhibitors can also increase blood pressure, induce or worsen cardiac failure and impair kidney function to the point of renal failure. In a recent unpublished trial, on the use of rofecoxib to prevent colon cancer, the risk of myocardial infarction and stroke after 18 months of treatment was high enough to prompt the removal of rofecoxib from the market. If another COX-2 selective drug is prescribed for patients at risk of thrombosis it should be used at the lowest effective dose and for short periods wherever possible. Prophylaxis with low-dose aspirin or other anti-thrombotic treatment should be continued.
Introduction
The COX-2 selective inhibitors, such as rofecoxib and celecoxib, were introduced to decrease the gastrointestinal morbidity and mortality associated with older non-steroidal anti-inflammatory drugs (NSAIDs) which inhibit both the COX-1 and the COX-2 enzymes. However, confusion still surrounds the role of COX-2 selective inhibitors because of an increased risk of myocardial infarction and other thrombotic events.
This risk first emerged in the VIGOR study which involved over 8000 patients. Although the absolute risk was low, there was a significantly higher rate of myocardial infarction with rofecoxib (18 cases) than naproxen (3 cases). However, the dose of rofecoxib (50 mg/day) was twice the dose recommended to treat rheumatoid arthritis while naproxen was given at the appropriate anti-inflammatory dose (1000 mg/day). Further, this trial was conducted in patients with rheumatoid arthritis, an inflammatory disorder that is associated independently with increased risk of thrombosis, particularly myocardial infarction. In retrospect, about half the patients who had infarctions during the trial should have been taking low-dose aspirin as prophylaxis.
However, the trial did not allow patients to take aspirin. 1 There have been a large number of claims and counter-claims about the risk of myocardial infarction with the COX-2 selective inhibitors, particularly rofecoxib. These were based on retrospective analyses, other controlled studies in osteoarthritis and rheumatoid arthritis, epidemiological studies, meta-analyses of published and unpublished studies and a recent large controlled trial of lumiracoxib in over 18 000 patients. 2, 3 Most importantly, a recent unpublished trial on the use of rofecoxib to prevent colon cancer (the APPROVe study) found that treatment with rofecoxib was associated with a risk of myocardial infarction and stroke which became apparent after 18 months' treatment. The manufacturer has removed rofecoxib from the market because of this risk. Does the same risk apply to celecoxib, the other widely used COX-2 selective inhibitor presently available in Australia? Was this a class effect of COX-2 selective inhibitors and did increasing selectivity for COX-2 inhibition increase the risk? Did the underlying disease influence the findings? More importantly, should prescribers avoid COX-2 selective inhibitors in patients with vascular disease or a known risk of myocardial infarction? 4
Mechanisms of action
The analgesic and anti-inflammatory actions of NSAIDs including COX-2 selective inhibitors are due to their effective inhibition of prostaglandin synthesis catalysed by the COX-2 isoenzyme (Fig. 1 ). This isoenzyme is massively up-regulated in 
Thrombosis
As COX-2 selective inhibitors do not inhibit thromboxane A 2 synthesis they could be predicted to increase the risk of thrombosis. Thromboxane A 2 is not only a stimulus for platelet aggregation but also a powerful vasoconstrictor ( 
Advantages of COX-2 inhibitors
COX-2 selective inhibitors were developed to reduce the risk of gastrointestinal ulceration caused by non-selective NSAIDs.
By selectively inhibiting COX-2 they reduced the risk of upper gastrointestinal bleeding associated with other NSAIDs. In studies of rofecoxib and lumiracoxib, the absolute risk of serious upper gastrointestinal ulceration and bleeding is reduced by 50-60% or more compared to other NSAIDS. 1, 2 In the VIGOR study it was concluded that only 41 patients would need to be treated with rofecoxib rather than naproxen to avert one upper gastrointestinal event in a one-year period. 1 This figure was calculated from all patients in the trial and the number should be even smaller in patients who are at risk of upper gastrointestinal adverse reactions. This risk increases in patients with a history of peptic ulcer or bleeding, those taking anticoagulants and possibly patients taking oral glucocorticosteroids. If these patients require treatment with anti-inflammatory drugs, they should probably be prescribed COX-2 selective inhibitors rather than non-selective NSAIDs. 5 The bleeding tendency associated with NSAIDs and aspirin is not seen with COX-2 selective inhibitors. They or paracetamol should be used in patients taking anticoagulants or if post-surgical bleeding is likely and a mild analgesic is indicated.
COX-2 selective drugs have no efficacy advantage
As non-selective NSAIDs inhibit both COX-1 and COX-2 there was no reason to expect that COX-2 selective inhibitors would have greater efficacy because they only inhibited the isoenzyme responsible for inflammation. Unfortunately, consumers and some prescribers were under the false impression that these medicines would be more effective as well as safer. This is part Fig. 1 Scheme. 6 There is no evidence of increased efficacy of COX-2 selective inhibitors compared to conventional NSAIDs. The more inflammatory the condition, the more reasonable prescribing an NSAID becomes. Whatever the condition being treated, the lower the dose and the shorter the exposure to these drugs, the lower the risk is for upper gastrointestinal bleeding and ulceration. Optimally, the patient can match the intake of drug with their own need for analgesia, thereby reducing unnecessary exposure. Should the patient have an increased risk of upper gastrointestinal ulceration and bleeding then prescribing expensive COX-2 selective drugs can be justified as they become cost-effective in this situation. However, this needs to be tempered with concern for adverse effectsthose known to be associated with all NSAIDs and those that might be peculiar to COX-2 selective inhibitors.
Mechanisms of action of non-steroidal anti-inflammatory drugs

Adverse effects on renal function
If NSAIDs, including COX-2 selective inhibitors, are prescribed for patients with renal impairment, cardiac failure or hypertension, each patient should be monitored closely. 7, 8 This should include eliciting symptoms and signs of heart failure, measuring weight and blood pressure and monitoring plasma creatinine and electrolytes soon after starting the drug (for example 2-4 weeks) and at regular reasonable intervals depending on the individual case. If the patient is also elderly then the risk is further increased.
These patients are often prescribed low-dose aspirin or other platelet inhibitory therapy. The CLASS study suggested that the gastrointestinal safety advantage of celecoxib over a conventional NSAID is lost when low-dose aspirin is taken concomitantly. 9 This was again noted in the large study of lumiracoxib. 2 Other data have suggested that the gastrointestinal safety of a COX-2 selective inhibitor together with low-dose aspirin is greater than a combination of a non-selective NSAID with aspirin 10 , but this view is much less likely to be correct in the light of the lumiracoxib data. 2 However, low-dose aspirin should not be stopped if COX-2 selective inhibitors or other NSAIDs (despite their platelet inhibitory actions) are prescribed. In vitro studies indicate that celecoxib is somewhat less COX-2 selective than rofecoxib and may therefore be safer in patients at risk of thrombosis. There has not been as strong a signal for thrombotic risk with celecoxib 11, 12 , but further studies are clearly required as placebo-controlled trials of the size and duration of APPROVe are not yet available.
Unknowns
Until more data are available, the COX-2 selective inhibitors should only be used in low doses and for short periods.
Low-dose aspirin or other anti-thrombotic treatment should be continued in patients at risk of thrombosis.
